Trending Movers to Watch: SAP SE (ADR)(NYSE:SAP), Acorda Therapeutics Inc (NASDAQ:ACOR), PacWest Bancorp (NASDAQ:PACW)

On Thursday, Shares of SAP SE (ADR)(NYSE:SAP), subtract -1.88% and closed at $84.35 in the last trading session. The last trading range of the stock ranges between $83.65 and $85.53. Deutsche Bank recently declared the lineup for its Depositary Receipts Virtual Shareholder Conference (“dbVIC”) on November 16th and 17th, featuring live webcast presentations from international companies with American Depositary Receipt (ADR) programs in the US.

Representatives from participating companies based in Australia, Denmark, France, Germany, Hong Kong, Japan, South Africa and the UK will respond to questions during formal presentations, and will also interact with shareholders via virtual trade booths. The conference is targeted to all types of shareholders in addition to analysts interested in non-US companies.

Acorda Therapeutics Inc (NASDAQ:ACOR), jumped 3.26% and closed at $20.60 in the last trading session. The last trading range of the stock ranges between $20.10 and $20.95. The company’s Market capitalization is $1.05 Billion with the total Outstanding Shares of 46.11 million. Acorda Therapeutics, Inc. (Nasdaq:ACOR) declared that Ron Cohen, M.D., President and CEO of Acorda Therapeutics, will present at the Stifel 2016 Healthcare Conference on Wednesday, November 16 at 11:00am.

PacWest Bancorp (NASDAQ:PACW), jumped 5.76% and closed at $47.91 in the last trading session. The last trading range of the stock ranges between $45.87 and $48.20. During the 52-week trading session the minimum price at which share price traded, registered at $29.05 and reached to max level of $48.20. Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, and Square 1 Bank, a division of Pacific Western Bank, declared they have reached a contract for a $20 million credit facility. Proceeds from the facility will provide working capital to support Cidara’s CD101 and CD201 programs which are in development to treat serious fungal and multi-drug resistant bacterial infections.

“The additional capital made available by this credit facility will provide Cidara with financial flexibility, additional operating capital, and funding to advance the development activities of our pipeline of drug candidates,” said Jeff Stein, Ph.D., president and CEO of Cidara. “We appreciate the support of Square 1, and its confidence in our programs and the Cidara administration team.”

Leave a Reply

Your email address will not be published. Required fields are marked *